Table 3.
Multivariate analysis of prognostic factors of NPC patients
| Variable | PFS | DMFS | LRFS | OS | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| Sex (male vs. female) | 1.273 (0.856-1.895) | 0.233 | 1.296 (0.798-2.105) | 0.294 | 0.890 (0.477-1.661) | 0.714 | 1.532 (0.805-2.916) | 0.194 |
| Age (≥45 vs. <45) | 1.151 (0.852-1.555) | 0.360 | 1.063 (0.736-1.536) | 0.744 | 1.079 (0.664-1.754) | 0.759 | 1.718 (1.054-2.798) | 0.030 |
| Smoking (Yes vs. No) | 0.996 (0.706-1.404) | 0.981 | 0.983 (0.644-1.500) | 0.937 | 1.171 (0.666-2.061) | 0.584 | 1.000 (0.592-1.687) | 0.999 |
| T stage (T4 vs. T1-3) | 1.163 (0.859-1.574) | 0.329 | 1.023 (0.705-1.484) | 0.905 | 1.661 (1.013-2.724) | 0.044 | 1.122 (0.700-1.799) | 0.633 |
| N stage (N2-3 vs. N0-1) | 1.256 (0.900-1.753) | 0.180 | 1.646 (1.071-2.531) | 0.023 | 1.024 (0.612-1.716) | 0.927 | 1.702 (0.988-2.931) | 0.055 |
| EBV DNA change subgroup | <0.001 | <0.001 | <0.001 | <0.001 | ||||
| Pre- & Post- | Reference | Reference | Reference | Reference | Reference | Reference | Reference | Reference |
| Pre+ & Post- | 1.878 (1.252-2.818) | 0.002 | 1.773 (1.053-2.983) | 0.031 | 1.814 (0.970-3.389) | 0.062 | 1.912 (0.959-3.812) | 0.066 |
| Pre- & Post+ | 4.167 (2.032-8.547) | <0.001 | 7.254 (3.338-15.762) | <0.001 | 3.388 (1.104-10.400) | 0.033 | 4.582 (1.442-14.554) | 0.010 |
| Pre+ & Post+ | 9.678 (6.019-15.559) | <0.001 | 10.488 (5.924-18.568) | <0.001 | 5.628 (2.553-12.404) | <0.001 | 11.587 (5.576-24.080) | <0.001 |
Abbreviations: PFS: progression-free survival; DMFS: distant metastasis-free survival; LRFS: locoregional relapse-free survival; OS: overall survival; HR: hazard ratio; CI: confidence interval.